Investigating the Differential Regulation of Cell Surface GAG in Cancer: Using NGPD to Isolate Cancer Cell Specific PeptidesTools Hardie, Derek T. (2024) Investigating the Differential Regulation of Cell Surface GAG in Cancer: Using NGPD to Isolate Cancer Cell Specific Peptides. PhD thesis, University of Nottingham.
AbstractGlioblastoma is the most prevalent primary malignant brain tumour in adults. The standard treatment consists of maximal surgical resection, chemotherapy using the alkylating agent temozolomide (TMZ), and radiotherapy. Despite current treatments, long term survival remains low, and there are high recurrence rates. Gene therapy, which aims to generate a therapeutic effect via the delivery of exogenous nucleic acids, could offer a new approach. However, to be successful gene therapy requires delivery vehicles which are able to facilitate uptake into target cells whilst protecting genetic cargo. The glycosaminoglycan (GAG)-binding Enhanced Transduction (GET)-peptide is able to electrostatically form complexes with nucleic acids and facilitate enhanced transfection in a non-specific manner via a synergistic effect between a GAG-binding domain and cell penetrating peptide (CPP). In order to modify the peptide to specifically deliver to glioblastoma cells Next Generation Phage Display (NGPD) was employed to screen for GET-variants specific to KNS42 cells, resulting in the peptide termed KR being identified. After screening, multiple modified versions of the peptide were made to include LK15 domains, which are present in the GET peptide.
Actions (Archive Staff Only)
|